DFFN - Diffusion Pharmaceuticals Inc.
| Previous Close | 0.4100 |
| Open | 0.3791 |
| Bid | 0.4100 x 1200 |
| Ask | 0.4240 x 800 |
| Day's Range | 0.3511 - 0.4500 |
| 52 Week Range | 0.2100 - 6.4900 |
| Volume | 7,899,528 |
| Avg. Volume | 4,227,919 |
| Market Cap | 14.883M |
| Beta (5Y Monthly) | 0.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.7590 |
| Earnings Date | Mar 16, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.50 |
- Zacks Small Cap Research
DFFN: Evaluating TSC as Potential Treatment for ARDS…
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating TSC as Treatment for ARDS On April 1, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company will be evaluating its lead development compound, trans sodium crocetinate (TSC), for the treatment of acute respiratory distress syndrome (ARDS) as a result of infection with the novel
- GlobeNewswire
Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
CHARLOTTESVILLE, Va., April 01, 2020 -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.
- GlobeNewswire
Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus
The LA County Fire Department has informed us that, due to the necessity to respond to the pandemic, it is suspending future training of first responders who had been scheduled to participate in the trial protocol. Such disruptions are expected to delay the Company’s previously announced timeline for study completion.
- Simply Wall St.
Is Diffusion Pharmaceuticals (NASDAQ:DFFN) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- GlobeNewswire
CORRECTION -- Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update
$16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 18, 2020 -- In the news release.
- GlobeNewswire
Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update
$16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 17, 2020 -- Diffusion.
- GlobeNewswire
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
Dr. Gainer will continue to serve as both an advisor to the Company and as a member of the board of directors. In recognition of the advancement of the TSC technology into the clinic, the Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.
- GlobeNewswire
Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC
This patent relates to pharmaceutical compositions of trans sodium crocetinate (“TSC”) and a cyclodextrin for use in therapy. Specifically claimed are TSC compositions are for use in conjunction with radiation or chemotherapy. Secondary claims relate to various compositions of TSC.
- GlobeNewswire
Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors
CHARLOTTESVILLE, Va., Jan. 10, 2020 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company.
- Zacks Small Cap Research
DFFN: Highly Encouraging Data from Run-in Portion of Phase 3 GBM Trial…
By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Encouraging Data for Dose Escalation Run-in of Phase 3 GBM Trial On December 10, 2019, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced the presentation of highly encouraging data from the 19 patient run-in portion of the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial of TSC in
- Insider Monkey
Hedge Funds Have Never Been More Bullish On Diffusion Pharmaceuticals Inc. (DFFN)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
- GlobeNewswire
Diffusion Pharmaceuticals Inc. Announces Closing of $3.5 Million Offering Priced At-the-Market
The Company also issued 6,266,787 unregistered warrants to the institutional investors in a concurrent private placement to purchase one share of common stock for each share of common stock purchased with an exercise price of $0.4335 per share. The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, were approximately $3.5 million.
- GlobeNewswire
CORRECTING and REPLACING – Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
In a release issued under the same headline earlier today by Diffusion Pharmaceuticals Inc. (DFFN), please note that the pricing and figures in the first paragraph of the release have changed. The Company also agreed to issue to the institutional investors in a concurrent private placement unregistered warrants to purchase up to 6,266,787 shares of common stock, at an exercise price of $0.4335 per share. The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, are expected to be approximately $3.5 million.
- GlobeNewswire
Diffusion Pharmaceuticals Inc. Announces $3.5 Million Registered Direct Offering Priced At-the-Market
The Company also agreed to issue to the institutional investors in a concurrent private placement unregistered warrants to purchase up to 6,266,787 shares of common stock, at an exercise price of $0.4335 per share and a purchase price of $0.125 per warrant, for aggregate gross proceeds of approximately $0.78 million. The warrants will be exercisable upon issuance and will expire five and one-half years following the date of issuance.
- Benzinga
The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 10) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics ...
- GlobeNewswire
Diffusion Pharmaceuticals Presents Data Suggesting Optimized TSC Dosing Regimen Increases Survival in Newly Diagnosed Inoperable Glioblastoma Patients
Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces the presentation of data signaling increased survival in inoperable glioblastoma multiforme (GBM) patients enrolled in the 19-patient lead-in portion of its open-label, dose-escalation Phase 3 study with Trans Sodium Crocetinate (TSC) plus standard of care (SOC). Chief Scientific Officer John Gainer, Ph.D. presented these findings today at the inaugural Glioblastoma Drug Development Summit in Boston, sponsored by Hanson Wade. Dr. Gainer’s presentation included earlier research demonstrating that TSC safely reduces tumor hypoxia by a novel mechanism of action, making the tumor up to 3 times more susceptible to radiation and chemotherapy.
- Benzinga
The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 19) 89bio Inc (NASDAQ: ETNB ) (IPOed Nov. 11) Allergan ...
- GlobeNewswire
Diffusion Pharmaceuticals Presents Early Findings Showing Increased Survival in Lead-in Portion of Phase 3 Glioblastoma Study with TSC plus Standard of Care
Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces increased survival in inoperable glioblastoma patients enrolled in the 19-patient, open-label, dose-escalation lead-in portion of its Phase 3 study with Trans Sodium Crocetinate (TSC) plus standard of care (SOC). John Gainer, Ph.D., the Company’s chief scientific officer, will present details of these findings at the inaugural Glioblastoma Drug Development Summit being held in Boston December 10-11, and sponsored by Hanson Wade. Dr. Gainer’s slide presentation will be posted to the Company’s website at www.diffusionpharma.com immediately prior to the conference.
- GlobeNewswire
Diffusion Pharmaceuticals Announces Closing of $4.0 Million Public Offering
CHARLOTTESVILLE, Va., Nov. 15, 2019 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”) a clinical-stage biotechnology company.
- GlobeNewswire
Diffusion Pharmaceuticals Announces $4.0 Million Public Offering
Diffusion Pharmaceuticals Inc. (DFFN) (“Diffusion” or the “Company”), a clinical-stage biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that it has priced a public offering of an aggregate of 11,428,572 shares of common stock (or common stock equivalents) of the Company, together with accompanying common warrants, at a public offering price of $0.35 per share and associated warrants. Each share of common stock (or common stock equivalent) sold in the offering was sold collectively with (i) a common warrant to purchase one share of common stock expiring eighteen months from the date of issuance and (ii) a common warrant to purchase one share of common stock expiring five years from the date of issuance.
- GlobeNewswire
Diffusion Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Business Update
Commenced Patient Enrollment in Phase 2 On-Ambulance TSC Clinical Trial for the Treatment of Stroke Reported Favorable Safety Data in Glioblastoma Multiforme Phase 3 Run-in.
- GlobeNewswire
First Patient Enrolled in Diffusion Pharmaceuticals’ Phase 2 On-Ambulance Clinical Trial with TSC for the Treatment of Stroke
Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, announces that the first patient has been enrolled in its Phase 2 on-ambulance study evaluating trans sodium crocetinate (TSC) for the treatment of stroke. The 160-patient trial, named PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC), will involve 23 hospitals, working closely with approximately 150 emergency medical transport groups across Central Virginia and urban, suburban and rural areas in Los Angeles County. Diffusion expects enrollment at the University of Los Angeles (UCLA) to begin later this quarter, where about 20 hospital sites will be participating.
- Simply Wall St.
Will Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Need To Raise More Money?
Trailing twelve-month data shows us that Diffusion Pharmaceuticals Inc.'s (NASDAQ:DFFN) earnings loss has accumulated...
- GlobeNewswire
Diffusion Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Diffusion Pharmaceuticals Inc. (DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today announced that management will present at the H.C. Wainwright 21st Annual Global Investment Conference on Monday, September 9, 2019 at 4:40 p.m. Eastern Time. The conference will be held September 8-10 at the Lotte New York Palace Hotel in New York City. To listen to the presentation live, investors may visit the Investor Relations section of Diffusion Pharmaceuticals’ website at www.diffusionpharma.com.
- Zacks Small Cap Research
DFFN: Positive Safety Data for Dose Escalation Portion of Phase 3 GBM Trial…
On July 23, 2019, Diffusion Pharmaceuticals, Inc. (DFFN) announced that the Data Safety Monitoring Board (DSMB) has unanimously recommended continuing the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial following a dose escalation run-in phase with the company’s lead compound, trans sodium crocetinate (TSC). A total of 19 patients were treated with four doses of TSC: 0.25, 0.5, 1.0, and 1.5 mg/kg.
